Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2321962
Max Phase: Preclinical
Molecular Formula: C17H10BrN3O4
Molecular Weight: 400.19
Molecule Type: Small molecule
Associated Items:
ID: ALA2321962
Max Phase: Preclinical
Molecular Formula: C17H10BrN3O4
Molecular Weight: 400.19
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C1Nc2c(Br)cccc2/C1=C1/Nc2cc(C(=O)O)ccc2/C1=N\O
Standard InChI: InChI=1S/C17H10BrN3O4/c18-10-3-1-2-9-12(16(22)20-13(9)10)15-14(21-25)8-5-4-7(17(23)24)6-11(8)19-15/h1-6,19,25H,(H,20,22)(H,23,24)/b15-12-,21-14+
Standard InChI Key: GGOSCGOWOVGYLY-HQMCVCOQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 400.19 | Molecular Weight (Monoisotopic): 398.9855 | AlogP: 3.11 | #Rotatable Bonds: 1 |
Polar Surface Area: 111.02 | Molecular Species: ACID | HBA: 5 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.53 | CX Basic pKa: | CX LogP: 2.22 | CX LogD: -1.07 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.33 | Np Likeness Score: 0.05 |
1. Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, Magiatis P, Ferandin Y, Durieu E, Lozach O, Cappel D, Soundararajan M, Filippakopoulos P, Sherman W, Knapp S, Meijer L, Mikros E, Skaltsounis AL.. (2013) Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases., 4 (1): [PMID:23336033] [10.1021/ml300207a] |
2. Pergola C, Gaboriaud-Kolar N, Jestädt N, König S, Kritsanida M, Schaible AM, Li H, Garscha U, Weinigel C, Barz D, Albring KF, Huber O, Skaltsounis AL, Werz O.. (2014) Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase., 57 (9): [PMID:24697244] [10.1021/jm401740w] |
3. Gaboriaud-Kolar N, Myrianthopoulos V, Vougogiannopoulou K, Gerolymatos P, Horne DA, Jove R, Mikros E, Nam S, Skaltsounis AL.. (2016) Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines., 79 (10): [PMID:27726390] [10.1021/acs.jnatprod.6b00285] |
Source(1):